Impact of AIT on Allergic Rhinitis and Asthma Using Real World Evidence
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 92,048
- 试验地点
- 1
- 主要终点
- Allergic rhinitis medication use
研究概览
简要总结
The study will assess the effectiveness of AIT treatment in real clinical practice in Germany.
详细描述
Allergic rhinitis (AR) affects 23-30% of the European population and is associated with a major burden on public health. AR and asthma frequently coexist, and may both be caused by allergen exposure. While the efficacy of AIT, i.e. reduce symptoms and medication use in patients with AR and asthma, has been demonstrated in several randomized clinical trials, little is known about the use and effectiveness of AIT in real world clinical practice.
This study is a retrospective database study that uses real-world data from Germany. The study population consists of AR patients with and without asthma treated with AIT and matched controls not treated with AIT. Information about the patients and treatments will be obtained from the 'BKK German Sickness Fund Database' from 2007 until 2017.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •AIT prescription 12 months before the index event (in the pre-index period) for the AIT treatment group
研究组 & 干预措施
AIT Cohort
Allergic rhinitis patients with and without asthma treated with AIT
干预措施: Allergy immunotherapy (AIT) (Drug)
结局指标
主要结局
Allergic rhinitis medication use
时间窗: From pre-index year to follow-up year(s), assessed from 2007 and up to 2017
Number of patients with an AR prescription and number of prescriptions by drug class
次要结局
- Asthma medication use(From pre-index to follow-up year(s), assessed from 2007 and up to 2017)
- Change in asthma disease severity(From pre-index to follow-up year(s), assessed from 2007 and up to 2017)